{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:03:26Z","timestamp":1793754206624,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007156","name":"Innovation and Technology Commission - Hong Kong","doi-asserted-by":"publisher","award":["MRP\/031\/21"],"award-info":[{"award-number":["MRP\/031\/21"]}],"id":[{"id":"10.13039\/501100007156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriasis is a long-term inflammatory skin disease. A novel herbal formula containing nine Chinese herbal medicines, named Inflammation Skin Disease Formula (ISDF), has been prescribed in clinics for decades.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To investigate the efficacy and action mechanisms of ISDF on psoriasis using imiquimod (IMQ) and Interleukin-23 (IL-23)-induced models in mice and reveal the pharmacokinetics profile of ISDF in rats.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Topical administration of IMQ and intradermal injection with IL-23 respectively induced skin lesions like psoriasis on the dorsal area of Balb\/c and C57 mice. The mice's body weight, skin thickness, and psoriasis area and severity index (PASI) were assessed weekly. SD rats were used in the pharmacokinetics study and the contents of berberine and baicalin were determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The PASI scores and epidermal thickness of mice were markedly decreased after ISDF treatment in both models. ISDF treatment significantly decreased the contents of IL-17A and IL-22 in the serum of IMQ- and IL-23-treated mice. Importantly, ISDF markedly downregulated IL-4, IL-6, IL-1\u03b2, and tumor necrosis factor \u03b1 (TNF-\u03b1) gene expression, and the phosphorylation of NF-\u03baB p65, JNK, ERKs and MAPK p38 in IMQ-treated mice. The protein phosphorylation of Jak1, Jak2, Tyk2 and Stat3 was significantly mitigated in the ISDF-treated groups. The absorption of baicalin and berberine of ISDF through the gastrointestinal tract of rats was limited, and their distribution and metabolism in rats were also very slow, which suggested ISDF could be used in the long-term application.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ISDF has a strong anti-psoriatic therapeutic effect on mouse models induced with psoriasis through IMQ and IL-23, which is achieved by inhibiting the activation of the Jak\/Stat3-activated IL-23\/Th17 axis and the downstream NF-\u03baB signalling and MAPK signalling pathways. ISDF holds great potential to be a therapy for psoriasis and should be further developed for this purpose.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13020-024-00951-9","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T02:01:36Z","timestamp":1718071296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Improvement effects of a novel Chinese herbal formula in imiquimod and IL-23-stimulated mouse models of psoriasis"],"prefix":"10.1186","volume":"19","author":[{"given":"Lan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Xing","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Xia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu-Po","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5032-0366","authenticated-orcid":false,"given":"Yan-Fang","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Xiu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"issue":"6","key":"951_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/0190-9622(90)70155-B","volume":"22","author":"JD Bernhard","year":"1990","unstructured":"Bernhard JD. Auspitz sign is not sensitive or specific for psoriasis. J Am Academy Dermatol. 1990;22(6):1079\u201381.","journal-title":"J Am Academy Dermatol"},{"key":"951_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880201","volume":"13","author":"J Bu","year":"2022","unstructured":"Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol. 2022;13: 880201.","journal-title":"Front Immunol"},{"issue":"11","key":"951_CR3","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.3390\/ijms23116130","volume":"23","author":"VS Krishnan","year":"2022","unstructured":"Krishnan VS, K\u00f5ks S. Transcriptional basis of psoriasis from large scale gene expression studies: the importance of moving towards a precision medicine approach. Int J Mol Sci. 2022;23(11):6130.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"951_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","volume":"84","author":"S Mehrmal","year":"2021","unstructured":"Mehrmal S, Uppal P, Nedley N, Giesey RL, Delost GR. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the global burden of disease study 2017. J Am Acad Dermatol. 2021;84(1):46\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"951_CR5","volume":"12","author":"FM Sahi","year":"2020","unstructured":"Sahi FM, Masood A, Danawar NA, Mekaiel A, Malik BH. Association between psoriasis and depression: a traditional review. Cureus. 2020;12(8): e9708.","journal-title":"Cureus"},{"issue":"19","key":"951_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"6","key":"951_CR7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/jid.2009.59","volume":"129","author":"A Di Cesare","year":"2009","unstructured":"Di Cesare A, Di Meglio P, Nestle FO. The IL-23\/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339\u201350.","journal-title":"J Invest Dermatol"},{"key":"951_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","volume":"9","author":"MP Sch\u00f6n","year":"2018","unstructured":"Sch\u00f6n MP, Erpenbeck L. The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;9:1323.","journal-title":"Front Immunol"},{"issue":"5","key":"951_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1189\/jlb.1213633","volume":"95","author":"X Chen","year":"2014","unstructured":"Chen X, Oppenheim JJ. Th17 cells and Tregs: unlikely allies. J Leukoc Biol. 2014;95(5):723\u201331.","journal-title":"J Leukoc Biol"},{"issue":"12","key":"951_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1600-0625.2010.01134.x","volume":"19","author":"P Muhr","year":"2010","unstructured":"Muhr P, Renne J, Schaefer V, Werfel T, Wittmann M. Primary human keratinocytes efficiently induce IL-1-dependent IL-17 in CCR6+ T cells. Exp Dermatol. 2010;19(12):1105\u20137.","journal-title":"Exp Dermatol"},{"issue":"3","key":"951_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjd.15928","volume":"178","author":"AM Drucker","year":"2018","unstructured":"Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: international eczema council consensus statement. Br J Dermatol. 2018;178(3):768\u201375.","journal-title":"Br J Dermatol"},{"issue":"12","key":"951_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/1744666X.2016.1202115","volume":"12","author":"A Cline","year":"2016","unstructured":"Cline A, Hill D, Lewallen R, Feldman SR. Current status and future prospects for biologic treatments of psoriasis. Expert Rev Clin Immunol. 2016;12(12):1273\u201387.","journal-title":"Expert Rev Clin Immunol"},{"key":"951_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114021","volume":"274","author":"L Wang","year":"2021","unstructured":"Wang L, Xian Y-F, Hu Z, Loo SKF, Ip SP, Chan WY, et al. Efficacy and action mechanisms of a Chinese herbal formula on experimental models of atopic dermatitis. J Ethnopharmacol. 2021;274: 114021.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"951_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jaci.2020.04.034","volume":"147","author":"MP Schon","year":"2021","unstructured":"Schon MP, Manzke V, Erpenbeck L. Animal models of psoriasis-highlights and drawbacks. J Allergy Clin Immunol. 2021;147(2):439\u201355.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"951_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cpim.71","volume":"125","author":"TP Singh","year":"2019","unstructured":"Singh TP, Zhang HH, Hwang ST, Farber JM. IL-23 and Imiquimod-induced models of experimental psoriasis in mice. Curr Protoc Immunol. 2019;125(1): e71.","journal-title":"Curr Protoc Immunol"},{"issue":"11","key":"951_CR16","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1172\/JCI93396","volume":"127","author":"TR Matos","year":"2017","unstructured":"Matos TR, O\u2019Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T cell clones. J Clin Invest. 2017;127(11):4031\u201341.","journal-title":"J Clin Invest"},{"key":"951_CR17","first-page":"4070","volume":"2008","author":"MH Ahmad Fadzil","year":"2008","unstructured":"Ahmad Fadzil MH, Ihtatho D, Affandi AM, Hussein SH. Objective assessment of psoriasis erythema for PASI scoring. Annu Int Conf IEEE Eng Med Biol Soc. 2008;2008:4070\u20133.","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"issue":"1","key":"951_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/10717544.2022.2036870","volume":"29","author":"Q Yu","year":"2022","unstructured":"Yu Q, Li M, Chen H, Xu L, Cheng J, Lin G, et al. The discovery of berberine erythrocyte-hemoglobin self-assembly delivery system: a neglected carrier underlying its pharmacokinetics. Drug Deliv. 2022;29(1):856\u201370.","journal-title":"Drug Deliv"},{"key":"951_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114032","volume":"199","author":"HB Chen","year":"2021","unstructured":"Chen HB, Luo CD, Ai GX, Wang YF, Li CL, Tan LH, et al. A comparative investigation of the interaction and pharmacokinetics of hemoglobin with berberine and its oxymetabolite. J Pharm Biomed Anal. 2021;199: 114032.","journal-title":"J Pharm Biomed Anal"},{"key":"951_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154346","volume":"104","author":"L Wang","year":"2022","unstructured":"Wang L, Hu Z, Yang W, Loo SKF, Ip SP, Xian YF, et al. Anti-atopic dermatitis effect of a modified Huang-Lian-Jie-Du decoction and its active fraction on 2,4-dinitrobenzene and MC903-induced mouse models. Phytomedicine. 2022;104: 154346.","journal-title":"Phytomedicine"},{"issue":"1","key":"951_CR21","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/ncomms2566","volume":"4","author":"A Walter","year":"2013","unstructured":"Walter A, Sch\u00e4fer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, et al. Aldara activates TLR7-independent immune defence. Nat Commun. 2013;4(1):1560.","journal-title":"Nat Commun"},{"issue":"4","key":"951_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018266","volume":"6","author":"WR Swindell","year":"2011","unstructured":"Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS ONE. 2011;6(4): e18266.","journal-title":"PLoS ONE"},{"key":"951_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/ITT.S240891","volume":"10","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T. The role of IL-17 cytokines in psoriasis. Immunotargets Ther. 2021;10:409\u201318.","journal-title":"Immunotargets Ther"},{"key":"951_CR24","doi-asserted-by":"publisher","first-page":"7420823","DOI":"10.1155\/2020\/7420823","volume":"2020","author":"A Michalak-Stoma","year":"2020","unstructured":"Michalak-Stoma A, Bartosi\u0144ska J, Kowal M, Raczkiewicz D, Krasowska D, Chodorowska G. IL-17A in the psoriatic patients\u2019 serum and plaque scales as potential marker of the diseases severity and obesity. Mediators Inflamm. 2020;2020:7420823.","journal-title":"Mediators Inflamm"},{"issue":"3","key":"951_CR25","first-page":"1","volume":"26","author":"RD Gotesman","year":"2021","unstructured":"Gotesman RD, Vender R. Bimekizumab for moderate-to-severe plaque psoriasis. Skin Ther Lett. 2021;26(3):1\u20134.","journal-title":"Skin Ther Lett"},{"issue":"4","key":"951_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","volume":"11","author":"L Puig","year":"2021","unstructured":"Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, et al. Efficacy and safety of netakimab, a novel anti-il-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis results of a 54-week randomized double-blind placebo-controlled planeta clinical trial. Dermatol Ther (Heidelb). 2021;11(4):1319\u201332.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"4","key":"951_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5114\/ada.2018.77665","volume":"35","author":"M Pirowska","year":"2018","unstructured":"Pirowska M, Obtu\u0142owicz A, Lipko-Godlewska S, Go\u017adzialska A, Podolec K, Wojas-Pelc A. The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor \u03b1 in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Postepy Dermatol Alergol. 2018;35(4):360\u20136.","journal-title":"Postepy Dermatol Alergol"},{"issue":"2","key":"951_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173\u201392.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"951_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2040622318759282","volume":"9","author":"TC Chan","year":"2018","unstructured":"Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111\u20139.","journal-title":"Ther Adv Chronic Dis"},{"key":"951_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","volume":"31","author":"EJ Hillmer","year":"2016","unstructured":"Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016;31:1\u201315.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"19","key":"951_CR31","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.3390\/jcm10194307","volume":"10","author":"S S\u0142uczanowska-G\u0142\u0105bowska","year":"2021","unstructured":"S\u0142uczanowska-G\u0142\u0105bowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of janus kinase inhibitors in therapy of psoriasis. J Clin Med. 2021;10(19):4307.","journal-title":"J Clin Med"},{"issue":"4","key":"951_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/10600280231153863","volume":"58","author":"TM Truong","year":"2024","unstructured":"Truong TM, Pathak GN, Singal A, Taranto V, Rao BK. Deucravacitinib: the first FDA-approved oral TYK2 inhibitor for moderate to severe plaque psoriasis. Ann Pharmacother. 2024;58(4):416\u201327.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"951_CR33","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1016\/j.apsb.2022.08.022","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H, et al. New opportunities and challenges of natural products research: When target identification meets single-cell multiomics. Acta Pharm Sin B. 2022;12(11):4011\u201339.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"951_CR34","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114455","volume":"14","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Wu Z, Yan W, Shao F, Ke B, Jiang X, et al. Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis. EMBO Mol Med. 2022;14(3): e14455.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"951_CR35","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-024-00672-y","volume":"3","author":"Y Ding","year":"2022","unstructured":"Ding Y, Ouyang Z, Zhang C, Zhu Y, Xu Q, Sun H, et al. Tyrosine phosphatase SHP2 exacerbates psoriasis-like skin inflammation in mice via ERK5-dependent NETosis. Med Comm. 2022;3(1): e120.","journal-title":"Med Comm"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-024-00951-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-024-00951-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-024-00951-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T14:58:16Z","timestamp":1732201096000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-024-00951-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1186\/s13020-024-00951-9","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}